What Ypozane (Osaterone) treats: main uses and benefits

Ypozane, which contains the active substance osaterone acetate, is a veterinary medication used primarily for the treatment of prostate-related issues in male dogs.

Treatment of Benign Prostatic Hyperplasia (BPH)

The primary use of Ypozane is the treatment of Benign Prostatic Hyperplasia, commonly referred to as BPH. This is a condition where the prostate gland becomes enlarged. BPH is highly common in intact (non-neutered) male dogs as they age, driven by the influence of male hormones, particularly testosterone and its derivative, dihydrotestosterone (DHT).

Mechanism of Action

Osaterone acetate is an anti-androgen. It works by blocking the transport of testosterone into the prostate and preventing the binding of dihydrotestosterone to the receptors within the prostate gland. By inhibiting these hormonal signals, the medication leads to a reduction in the size of the prostate gland.

Clinical Benefits and Symptoms Addressed

An enlarged prostate can cause significant discomfort and secondary health issues for a dog. By reducing the volume of the prostate gland, Ypozane helps alleviate the clinical signs associated with BPH, which may include:

• Difficulty urinating: A large prostate can press against the urethra, making it hard for the dog to pass urine.
• Defecation issues: The enlarged gland can also press against the rectum, leading to constipation or flattened stools.
• Pain and discomfort: Dogs with BPH may exhibit stiffness in their gait or general abdominal discomfort.
• Urethral discharge: In some cases, blood or fluid may leak from the urethra independently of urination.

Impact on Fertility

While Ypozane treats the symptoms of an enlarged prostate by targeting male hormones, it is designed to do so without permanently affecting the dog's reproductive capabilities. During the treatment period, sperm quality may be altered; however, clinical studies have shown that fertility typically returns to normal levels several weeks after the treatment course is completed. This makes it an option for breeding dogs where permanent surgical castration is not desired by the owner.

Regulatory References

1. European Medicines Agency

Eligibility Map: Who Can and Cannot Use Ypozane (Osaterone) — Official Regulatory Information

This section details the formal eligibility and exclusion criteria for Ypozane (Osaterone acetate) based strictly on authoritative governmental regulatory documents (e.g., EMA Summary of Product Characteristics).

Species and Sex Restriction

The most fundamental eligibility rule is the product's designation solely for veterinary use in male dogs. Its use is absolutely restricted to this target species and sex.

Contraindications and Exclusions

Category	Status (as per regulatory documents)
Formal Contraindications	None officially listed for the target species (male dogs).
Populations Excluded Due to Data Gaps	Use is not established for dogs weighing less than 3 kg bodyweight, indicating a practical exclusion zone.

Conditions Requiring Caution or Monitoring

Use of Ypozane is conditional and requires special consideration in certain patient groups:

• Liver Disease: Use must proceed with caution in dogs with a history of liver disease.
• Endocrine Conditions: Appropriate monitoring is required for dogs under stress or those diagnosed with hypoadrenocorticism.

These constraints establish a clear boundary for the drug's use, limiting administration to male dogs who meet specific weight requirements and are not subject to certain high-risk comorbidities without veterinary caution.

Ypozane (Osaterone) Interactions with other medicines and products

The official regulatory documentation for osaterone acetate (Ypozane) provides specific information regarding its interaction profile, which is summarized by the formal classification that no drug-drug interactions are known with other medicinal products.

---

Official Interaction Findings

The most essential finding is the absence of documented restrictions stemming from pharmacokinetic or pharmacodynamic interactions with other medicines. This classification means the regulatory label does not impose specific restrictions or prohibitions on co-administration based on known clinical risk.

---

Administration-Timing and Protein Binding

The regulatory label does contain a specific allowance for concurrent use, defining a permissive administration-timing rule: Osaterone may be administered concurrently with antimicrobials for the management of Benign Prostatic Hyperplasia (BPH) associated with prostatitis. This procedural statement clarifies that no mandatory time separation is required in this scenario.

Furthermore, the label addresses the potential for interaction related to plasma protein displacement. Osaterone acetate is highly bound to plasma proteins, but this binding is officially documented as not affected by other substances known to specifically bind to albumin. No specific interactions with food, alcohol, or herbal products are documented in the official labeling. The profile remains strictly defined by these label-based statements of non-interaction and one specific co-administration rule.

The mechanism of Osaterone acetate is based on a dual mechanism of action, targeting the pathways that regulate androgen-dependent cellular proliferation.

Direct Androgen Receptor Blockade

The primary antiandrogenic action is mediated by the active metabolite, 15beta-hydroxyosaterone acetate, which competitively binds to the Androgen Receptor (AR) within prostatic cells. This molecular blockade immediately prevents the formation of the active hormone-receptor complex, thereby suppressing the signal necessary for cellular proliferation; the physiological consequence is tissue volume reduction.

Local mathbf5alpha-Reductase Enzyme Inhibition

This domain involves the parent drug, Osaterone, inhibiting the 5alpha-Reductase enzyme, which is responsible for converting Testosterone into the potent growth stimulus, Dihydrotestosterone (DHT). By limiting the local supply of DHT and simultaneously blocking the AR, the drug reinforces the suppression of the growth pathway, resulting in a reduction in the volume of the affected tissue.

How to Use Ypozane (Osaterone) — Official Administration Guidelines

This information details the instructions for the administration and dosing of Ypozane (Osaterone acetate) tablets.

---

Administration Scope

Instruction Entity	Official Guideline
Route of Administration	Oral use.
Dosing Schedule	Once daily for 7 consecutive days. The target dose is 0.25 - 0.5 mg osaterone acetate per kilogram (kg) of body weight.
Timing in Relation to Meals	Tablets may be administered either directly into the mouth or with food.
Target Species	Male Dogs.

---

Official Dosing by Weight

The correct tablet strength must be selected based on the dog’s weight to ensure the specified dose is delivered. The available strengths are:

• 1.875 mg (for dogs 3 to 7.5 kg)
• 3.75 mg (for dogs 7.5 to 15 kg)
• 7.5 mg (for dogs 15 to 30 kg)
• 15 mg (for dogs 30 to 60 kg)

---

Procedural Structure and Re-treatment

The use of Ypozane is structured as a fixed, 7-day course. The maximum dose should not be exceeded. Following the initial course, re-treatment must not be considered any sooner than 5 months after the completion of the previous treatment. A decision to re-treat requires a full veterinary re-evaluation based on the recurrence of clinical signs and a current risk-benefit assessment.

Special Note on Handling: The official label advises that women of child-bearing age should avoid contact with the product or wear disposable gloves, and hands should be washed after administration.

Ypozane (Osaterone): Clinical Evidence Overview

Clinical trials have examined the use of Osaterone acetate (Ypozane) in the treatment of Benign Prostatic Hyperplasia (BPH) in male dogs. This condition involves the non-cancerous enlargement of the prostate gland, often resulting in clinical signs such as difficulty in urination or defecation.

---

Efficacy and Treatment Outcomes

Studies focused on assessing the reduction of prostate size and the severity of associated clinical signs. In a trial involving dogs with BPH, administration of osaterone acetate over a seven-day course resulted in observed clinical resolution and a reduction in mean prostate volume.

• Clinical Signs: Reports documented a significant decrease in the severity of BPH-related clinical scores within the first two to four weeks following the start of treatment. Complete clinical remission was achieved in a high percentage of subjects by the end of the four-week observation period.
• Prostate Volume: Research has shown a reduction in prostate volume, with one trial documenting a decrease to approximately 55% of the pre-treatment volume by Day 28. The duration of this effect in some studies extended for at least five to six months after the initial short course of treatment.

---

Safety and Tolerability Data

The most commonly observed events in clinical trials included transient modifications of appetite, either increased or decreased. Other uncommonly reported transient reactions included vomiting, diarrhea, polyuria/polydipsia, and lethargy. Studies have noted that a transient reduction in plasma cortisol concentration may occur in most treated animals, though this generally resolves without specific intervention. Osaterone is generally understood to be metabolised slowly, contributing to its long duration of effect.

Common questions about Ypozane (Osaterone) (FAQ)

---

Q: Is Ypozane a hormone or a steroid medication?

The active substance, osaterone acetate, is described in regulatory documents as a steroid anti-androgen. It is chemically related to progesterone, which is a naturally occurring steroid hormone, and possesses strong progestagen and anti-androgen properties.

---

Q: Does taking Ypozane require routine blood tests?

Official information indicates that the medication can cause a transient reduction of plasma cortisol concentration. This means the amount of cortisol, a hormone, may temporarily decrease. Due to this effect, monitoring in dogs with specific underlying conditions or those under stress may be necessary, as noted in the product information.

---

Q: Can you take Ypozane if you have existing kidney problems?

Regulatory documents do not list kidney disease or renal problems as a specific precaution or contraindication. However, official information does advise caution when the medicine is used in dogs with a history of liver disease, as safety in that population has not been fully investigated.

---

Q: What are the signs of a serious reaction to Ypozane that I should be aware of?

The regulatory safety profile classifies adverse reactions by frequency (e.g., very common, common, uncommon) and lists effects like vomiting, diarrhea, and lethargy. The documents do not classify any specific reaction as 'serious' or list signs of a life-threatening allergic reaction like anaphylaxis. All reported side effects in clinical trials were transient.

---

Q: Why do official documents state that Ypozane is not for use in children?

Ypozane is only authorized for use in male dogs. Regulatory documents advise that if a person, especially a child, accidentally ingests the product, immediate medical attention should be sought. This precaution is in place because the drug has hormonal activity and is not intended for human use.

---

Q: Is Ypozane a brand name, and what are its generics?

Ypozane is a registered brand name for this veterinary medicinal product. The active substance contained within it is osaterone acetate. Official regulatory information does not list or reference any generic alternatives to Ypozane.

---

Q: What happens if Ypozane is taken by someone who does not need it?

If accidental human ingestion occurs, the official label advises that medical advice should be sought immediately. Studies involving human males who received a single high dose indicated a sporadic and reversible decrease in sex hormone levels, but no lasting clinical effects were noted.

---

Q: Does the time of day matter when taking Ypozane?

The official administration instructions confirm that the tablets should be given once a day for the 7-day course. They can be given either directly into the mouth or mixed with food. The regulatory documents do not specify a preferred time of day, such as morning or evening.

---

Q: Is there research on Ypozane's use in elderly patients?

The drug is indicated for Benign Prostatic Hyperplasia (BPH) in male dogs, which is a condition typically observed in older animals. While the clinical trials naturally involve older dogs, the regulatory information does not contain a specific safety study for a formally defined 'elderly' subpopulation.

---

Q: Does Ypozane have a risk of withdrawal symptoms if stopped suddenly?

According to official regulatory documents, a formal withdrawal period is classified as 'Not applicable.' The regulatory information does not formally list dependency, abuse, or withdrawal symptoms as documented adverse events associated with the cessation of the 7-day course.

---

Q: How is Ypozane excreted from the body, based on official pharmacology data?

Pharmacology data shows that the drug and its metabolites are eliminated from the body primarily through the faeces via biliary excretion (about 60%). A lesser amount (about 25%) is eliminated through the urine.

---

Q: What research evidence exists about the long-term use of Ypozane?

The drug is administered as a fixed 7-day course. Research shows that the therapeutic effect is sustained, with clinical response and prostate volume reduction persisting for at least five months after the treatment course is finished. Pharmacokinetic data supports this prolonged duration of effect.

---

Q: Are there specific warnings about Ypozane and driving or operating machinery?

The medicine is for dogs. The regulatory safety profile lists adverse reactions like lethargy (drowsiness or sluggishness) and changes in activity. These effects may impact the treated animal’s normal mobility or alertness during and shortly after the treatment course.

---

Q: Are there any specific organs besides the liver that Ypozane is known to affect?

Yes, regulatory data indicates effects on several organs and systems. The drug primarily targets the prostate gland. However, side effects include a transient reduction in cortisol from the adrenal glands and occasional effects on the mammary glands (mammary hyperplasia and, rarely, galactorrhoea).

---

Q: What are the common reasons why a person might be advised to stop taking Ypozane?

The drug is formally contraindicated in dogs intended for breeding. The official label also advises using the product with caution in dogs with a history of liver disease. If the clinical response is much shorter than the expected 5 months, a re-evaluation of the dog’s diagnosis is necessary before a re-treatment decision is made.

---

Q: Is there a maximum time frame for which Ypozane is typically prescribed?

Treatment is administered as a fixed 7-day course, and the maximum dose for that course should not be exceeded. Re-treatment must not be considered until at least 5 months have passed since the completion of the previous treatment.

---

Q: Is it safe to get a vaccination while taking Ypozane?

Regulatory documents state that no known interactions are documented with other medicinal products. The specific risk or allowance for co-administration with vaccines is not explicitly discussed in the product information.

---

Q: What should a patient do if they accidentally take too much Ypozane?

Studies conducted on dogs with an overdose did not show any undesirable effects beyond a decrease in plasma cortisol concentration. No specific antidote is mentioned in the regulatory information.

How to Store and Dispose of Ypozane (Osaterone)

Official Storage Requirements

The regulatory documentation states that Ypozane (osaterone acetate) does not require any special storage conditions. The product is stable at ambient temperatures, and no specific restrictions on temperature, light, or moisture are mandated.

Storage Detail	Official Requirement
Environmental Control	No special storage conditions required.
Packaging	Store in the original aluminum/aluminum blister and carton box.
Shelf-Life	The shelf-life as packaged for sale is 3 years.
Child Protection	Must be kept out of the reach and sight of children.

Disposal Instructions

Disposal of any unused product or waste materials derived from Ypozane must be carried out in accordance with local requirements. This instruction ensures that the product is handled following established pharmaceutical and environmental waste protocols.